Schering AG Leukine enters Phase III for Crohn’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering AG is initiating a Phase III study of its white blood cell stimulator Leukine (sargramostim), the firm announces Aug. 28. The decision follows positive results from a recently completed 124-patient trial in moderately to severely active Crohn's. Results will not be disclosed until journal publication and presentation at medical meetings. Schering AG's U.S. subsidiary Berlex markets Leukine in the oncology market. The firm acquired Leukine from Immunex, which was required to divest the drug in connection with its acquisition by Neupogen manufacturer Amgen...